Amarin (AMRN) Q3 2025 Earnings Transcript

The company reported Q3 revenue of $1.281 billion, up 6% year over year on a constant-currency basis, and adjusted EBITDA rose 7% to $243 million with margin improving 400 bps sequentially to 19%. Management maintained full-year revenue guidance at $5.05 billion-$5.15 billion and raised the low end of adjusted EBITDA guidance to $870 million-$910 million, while noting tariff mitigation assumptions remain in place. Growth was driven by pharmaceuticals ($330 million, +7%), vision care ($736 million, +6%), and a surgical rebound as enVista recovered to 82% of pre-recall sales.

Analysis

BLCO is inflecting from a launch-heavy story to a self-funding compounding story: the mix shift toward premium surgical, dry eye, and contact lens innovation is now being offset by a structurally lower SG&A run-rate, which matters more than the headline revenue beat. The key second-order effect is operating leverage: once launch expense normalizes, even modest revenue growth can translate into outsized EBITDA and FCF expansion, which should compress the company’s perceived leverage risk and improve access to capital over the next 2-4 quarters.

The market is likely underappreciating how much of the dry-eye franchise is becoming a category-expansion engine rather than a share-take story. Management is effectively arguing that combo therapy broadens the addressable market and reduces physician friction, which means the competitive launch is more likely to raise the tide than blunt BLCO’s premium brands. That dynamic is especially relevant for payers and wholesalers: if Miebo/Xiidra can keep growing while coverage stays stable, the franchise can sustain above-market growth without escalating rebates at the same pace.

The surgical rebound is the cleanest near-term catalyst, but also the most fragile. The recovery from the recall appears operationally advanced, yet the remaining gap is now more about field focus and commercial normalization than demand, so the next 1-2 quarters should show margin and revenue upside if execution holds; however, any slip in premium IOL momentum would be read as a signal that the recovery was inventory-led rather than surgeon preference-led. Tariffs and China are the main external overhangs: they are manageable in 2025, but if policy turns against them, the low-margin segments and supply chain costs could absorb the first hit before top-line weakness becomes visible.

Consensus may be too anchored to BLCO as a levered turnaround and not enough on it as a cash-generative platform with optionality. If management continues to execute, the equity can rerate on multiple expansion rather than just earnings growth, because the market will start capitalizing a more durable FCF stream and lower execution beta. The biggest contradiction in the setup is that the better the operating performance, the less the market may need to pay for turnaround risk — creating room for a squeeze if the Investor Day reframes the 3-year plan credibly.

Key Decisions for Investors

• Long BLCO on a 3-6 month horizon: the setup favors EBITDA/FCF surprise as SG&A normalizes; target a 15-20% upside re-rate if Investor Day confirms margin expansion, with a stop if surgical recovery stalls sequentially.
• Buy BLCO Jan-2026 call spreads instead of common: express leverage to operating leverage and Investor Day catalyst while capping downside if tariff or China noise returns; favorable if the stock grinds higher on multiple expansion.
• Pair trade: long BLCO / short a slower-growth medtech or vision-care peer with less innovation leverage over the next 2 quarters; the relative-value thesis is that BLCO’s earnings revisions should accelerate faster than the group.
• Take profits on BLCO into any post-Investor-Day spike if the market extrapolates perfect execution; upside remains real, but the easy money is likely before 3Q26 once the market fully prices the margin reset.
• Watch for downside hedges via short-dated puts around China Singles’ Day and tariff headlines; those are the most plausible near-term dislocations that could interrupt the recovery narrative.